Clarke C L, Feil P D, Satyaswaroop P G
Department of Obstetrics and Gynecology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Endocrinology. 1987 Nov;121(5):1642-8. doi: 10.1210/endo-121-5-1642.
Regulation of progesterone receptor (PR) in human endometrial carcinoma was investigated in vivo in a multisite nude mouse tumor experimental system by estrogen administration and withdrawal. The cytosolic PR concentration was low in tumors grown in the absence of 17 beta-estradiol, but increased rapidly upon estrogen administration, reaching a maximal receptor concentration of 1.4-1.6 pmol/mg cytosol protein within 7 days. Protein blot analysis using a monoclonal antibody (hPRa 1) raised against PR from EnCa 101 showed no immunoreactivity in tumors grown in the absence of estrogen. Immunoreactive proteins of mol wt 116,000 and 81,000 were detectable 8 h after estrogen administration and increased in intensity as the cytosolic PR concentration increased. Interestingly, the protein of mol wt 116,000 was composed of mol wt isoforms and was detectable as a doublet 8 h after estrogen administration and finally as a triplet. The effect of estrogen withdrawal on EnCa 101 PR concentration and structure was determined by removal of 17 beta-estradiol pellets (200 pg/ml plasma) from EnCa 101-bearing animals after achievement of maximal tumor PR concentrations. The PR concentration in tumor cytosols decreased in a biphasic manner after estrogen removal, with the initial rapid phase having a half-life of around 2 days. Cytosolic PR was still detectable 21 days after estrogen withdrawal. Protein blot analysis showed that immunoreactive proteins of mol wt 116,000 and 81,000 were also detectable up to that time. Photoaffinity labeling with [3H]R5020 demonstrated that the 81,000 mol wt protein, as well as each of the triplet proteins at mol wt 116,000, was specifically photoaffinity labeled. The 116,000-mol wt protein was detected as a triplet on protein blots until 13 days after estrogen withdrawal, when diminution in the intensity of the highest mol wt triplet protein was noted.
在多部位裸鼠肿瘤实验系统中,通过给予雌激素和撤药,在体内研究了人子宫内膜癌中孕激素受体(PR)的调节。在无17β-雌二醇的情况下生长的肿瘤中,胞质PR浓度较低,但给予雌激素后迅速升高,7天内达到最大受体浓度1.4 - 1.6 pmol/mg胞质蛋白。使用针对EnCa 101的PR产生的单克隆抗体(hPRa 1)进行蛋白质印迹分析,发现在无雌激素的情况下生长的肿瘤中无免疫反应性。给予雌激素8小时后可检测到分子量为116,000和81,000的免疫反应性蛋白,且随着胞质PR浓度的增加,其强度增加。有趣的是,分子量为116,000的蛋白由不同分子量的异构体组成,给予雌激素8小时后可检测为双峰,最终变为三峰。在达到最大肿瘤PR浓度后,通过从携带EnCa 101的动物中取出17β-雌二醇药丸(血浆浓度为200 pg/ml),确定了雌激素撤药对EnCa 101 PR浓度和结构的影响。雌激素去除后,肿瘤胞质中的PR浓度呈双相下降,初始快速阶段的半衰期约为2天。雌激素撤药21天后仍可检测到胞质PR。蛋白质印迹分析表明,直至那时仍可检测到分子量为116,000和81,000的免疫反应性蛋白。用[3H]R5020进行光亲和标记表明,分子量为81,000的蛋白以及分子量为116,000的三峰蛋白中的每一个都被特异性光亲和标记。在雌激素撤药13天之前,分子量为116,000的蛋白在蛋白质印迹上检测为三峰,此时注意到最高分子量三峰蛋白的强度降低。